<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03241888</url>
  </required_header>
  <id_info>
    <org_study_id>2017-30-1</org_study_id>
    <nct_id>NCT03241888</nct_id>
  </id_info>
  <brief_title>Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia</brief_title>
  <official_title>Megestrol Acetate Plus LNG-IUS to Megestrol Acetate or LNG-IUS in Young Women With Endometrial Atypical Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai 6th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changning Maternity &amp; Infant Health Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To see if megestrol acetate plus Levonorgestrel-releasing intrauterine system (LNG-IUS) will
      not be inferior to returning the endometrial tissue to a normal state than megestrol acetate
      or LNG-IUS alone in patients with endometrial atypical hyperplasia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After diagnosed of endometrial atypical hyperplasia (EAH) by hysteroscopy, patients will be
      enrolled. Age, waist circumstances, blood pressure, basic history of infertility, blood
      pressure, serum lipid level and side effects will be collected. Blood tests, including
      fasting blood glucose (FBG), postprandial blood glucose (PBG), fasting insulin (FINS), SHBG,
      sex hormone levels, blood lipids and anti-m√ºllerian hormone(AMH) will be performed before
      treatment to evacuate their metabolic conditions.

      Patients are randomized to 1 of 3 treatment groups. Patients will receive MA (megestrol
      acetate) 160 mg by mouth daily for at least 3 months on Arm I. Patients will receive LNG-IUS
      insertion on Arm II and MA 160 mg plus LNG-IUS insertion on Arm III. Then an hysteroscope
      will be used to evaluate the endometrial condition every 3 months, and the findings will be
      recorded. For patients with EAH, complete response (CR) is defined as the reversion of
      endometrial atypical hyperplasia to proliferative or secretory endometrium; partial response
      (PR) is defined as regression to simple or complex hyperplasia without atypia; no response
      (NR) is defined as the persistence of the disease; and progressive disease (PD) is defined as
      the appearance of endometrial cancer in patients. Continuous therapies will be needed in PR,
      NR or PD.

      After completion of study treatment, 2 months of maintenance treatment will be recommended
      for patients with CR, and participants will be followed up for 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 4, 2017</start_date>
  <completion_date type="Anticipated">July 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 3, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological response rate</measure>
    <time_frame>From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pathological response time</measure>
    <time_frame>From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months</time_frame>
    <description>time of histologic regression from endometrial atypical hyperplasia to benign endometrium</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 2 years after the treatment for each patient</time_frame>
    <description>Common side effects from these drugs include weight gain, vaginal spotting and descent of sexuality. Severe side effects include thrombus and diseases related. The investigators will record any mental or body symptoms and evaluate the correlation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of relapse</measure>
    <time_frame>up to 2 years after the treatment for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of pregnancy</measure>
    <time_frame>up to 2 years after the treatment for each patient</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>up to 2 years after the treatment for each patient</time_frame>
    <description>The investigators designed a questionnaire to evaluate the compliance through treatment as side effects of oral megestrol acetate may be more common than LNG-IUS. Self Efficacy, physical activity and social support will be scored (1 to 5) and compared among each arm.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Economic consequences through study completion</measure>
    <time_frame>From date of randomization until the date of CR or date of hysterectomy, whichever came first, assessed up to 12 months</time_frame>
    <description>The investigators will evaluate whether the combination could shorten the therapeutic period, so that bring economic benefits.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Atypical Endometrial Hyperplasia</condition>
  <arm_group>
    <arm_group_label>MA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive megestrol acetate 160 mg by mouth daily for at least 3 months.Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LNG-IUS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MA+LNG-IUS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive MA (160mg po qd) plus LNG-IUS insertion for at least 3 months. Then every 3 months, an hysteroscope will be used to evaluate the endometrial condition, and the findings will be recorded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Megestrol Acetate</intervention_name>
    <description>At a dosage of 160 mg/day</description>
    <arm_group_label>MA</arm_group_label>
    <arm_group_label>MA+LNG-IUS</arm_group_label>
    <other_name>Megace</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Levonorgestrel-releasing Intrauterine System(LNG-IUS)</intervention_name>
    <description>Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.</description>
    <arm_group_label>LNG-IUS</arm_group_label>
    <arm_group_label>MA+LNG-IUS</arm_group_label>
    <other_name>Mirena Intrauterine Device</other_name>
    <other_name>Mirena</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primarily have a confirmed diagnosis of endometrial atypical hyperplasia based upon
             hysteroscopy

          -  Have a desire for remaining reproductive function or uterus

          -  Need to be able to undergo correlative treatment and follow-up

        Exclusion Criteria:

          -  Acute liver disease or liver tumor (benign or malignant) or renal dysfunction

          -  Pregnancy or suspicion of pregnancy

          -  Have a history of EAH and have disease relapse during Merina insertion

          -  Under treatment of high-dose progestin therapy more than 3 months in recent 6 months

          -  Congenital or acquired uterine anomaly including fibroids if they distort the uterine
             cavity

          -  Confirmed diagnosis of malignant tumor in genital system

          -  Acute severe disease such as stroke or heart infarction or a history of thrombosis
             disease

          -  Hypersensitivity or contradiction to any component of this product

          -  Ask for removal of the uterus or other conservative treatment

          -  Smoker(&gt;15 cigarettes a day)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaojun Chen, PhD</last_name>
    <phone>862163455050</phone>
    <email>cxjlhjj@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bingyi Yang, MD</last_name>
    <phone>862163455050</phone>
    <email>xiaomihaoku@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Obstetrics and Gynecology Hospital, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Chen, PhD</last_name>
      <phone>862163455055</phone>
      <email>cxjlhjj@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Bingyi Yang, MD</last_name>
      <phone>862163455055</phone>
      <email>xiaomihaoku@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Bingyi Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Gressel GM, Parkash V, Pal L. Management options and fertility-preserving therapy for premenopausal endometrial hyperplasia and early-stage endometrial cancer. Int J Gynaecol Obstet. 2015 Dec;131(3):234-9. doi: 10.1016/j.ijgo.2015.06.031. Epub 2015 Sep 8. Review.</citation>
    <PMID>26384790</PMID>
  </reference>
  <reference>
    <citation>Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, Seong SJ, Kim TJ, Kim JW, Kim SM, Bae DS, Nam JH. Long-term oncologic outcomes after fertility-sparing management using oral progestin for young women with endometrial cancer (KGOG 2002). Eur J Cancer. 2013 Mar;49(4):868-74. doi: 10.1016/j.ejca.2012.09.017. Epub 2012 Oct 13.</citation>
    <PMID>23072814</PMID>
  </reference>
  <reference>
    <citation>Orbo A, Vereide A, Arnes M, Pettersen I, Straume B. Levonorgestrel-impregnated intrauterine device as treatment for endometrial hyperplasia: a national multicentre randomised trial. BJOG. 2014 Mar;121(4):477-86. doi: 10.1111/1471-0528.12499. Epub 2013 Nov 28.</citation>
    <PMID>24286192</PMID>
  </reference>
  <reference>
    <citation>Wildemeersch D, Janssens D, Pylyser K, De Wever N, Verbeeck G, Dhont M, Tjalma W. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: long-term follow-up. Maturitas. 2007 Jun 20;57(2):210-3. Epub 2007 Jan 31.</citation>
    <PMID>17270370</PMID>
  </reference>
  <reference>
    <citation>Montz FJ, Bristow RE, Bovicelli A, Tomacruz R, Kurman RJ. Intrauterine progesterone treatment of early endometrial cancer. Am J Obstet Gynecol. 2002 Apr;186(4):651-7.</citation>
    <PMID>11967486</PMID>
  </reference>
  <reference>
    <citation>Chen M, Jin Y, Li Y, Bi Y, Shan Y, Pan L. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer. Int J Gynaecol Obstet. 2016 Jan;132(1):34-8. doi: 10.1016/j.ijgo.2015.06.046. Epub 2015 Oct 1.</citation>
    <PMID>26493012</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 12, 2017</study_first_submitted>
  <study_first_submitted_qc>August 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>October 22, 2017</last_update_submitted>
  <last_update_submitted_qc>October 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Obstetrics &amp; Gynecology Hospital of Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaojun Chen</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Levonorgestrel-releasing intrauterine system</keyword>
  <keyword>megestrol acetate</keyword>
  <keyword>Atypical Endometrial Hyperplasia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Endometrial Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levonorgestrel</mesh_term>
    <mesh_term>Megestrol</mesh_term>
    <mesh_term>Megestrol Acetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

